



Phase I Clinical Study on Antiplatelet Thrombolysin injection

(Hong Kong, 6 November 2009) - Lee's Pharmaceutical Holdings Limited ("Lee's Pharmaceutical" or the "Group", Stock Code: 8221), announced that it has successfully completed the dosing of the first two subjects in its Phase IA clinical trial in which Declotana[®] is being tested in 20 healthy subjects.

Declotana[®] is an antagonist of platelet 1b receptors being developed to prevent thrombosis in patients undergone PTCA and stenting as well as for treatment of ischemic heart diseases such as unstable angina. This single-dose study is to assess the safety and tolerability, as well as pharmacodynamic activity of Declotana[®]. To date, Declotana[®] appears safe and well tolerated and demonstrates expected pharmacodynamic activity.

"We are thrilled of reaching this important milestone for Declotana[®] development in China. It is our understanding that Declotana[®] is the first of its kind to be tested in human. It again demonstrates the Group's capability in new drug discovery and development. It is a great achievement for the Group's R&D team. We are looking forward to rapid clinical development of this proprietary product" stated Dr. Benjamin Li, the Chief Executive Officer of the Group.

About Declotana[®]

Declotana[®] - Antiplatelet Thrombolysin for injection, is a new molecular entity discovered and developed by the Group since 1995. It possesses the anti-platelet 1b receptors activity and is an effective anti-thrombosis agent model. Platelet 1b receptors are critical to platelet adhesion to damaged endothelin of blood vessel which leads to the activation of platelet and subsequent thrombus formation. Animal studies have shown that intravenous injection of Declotana[®] effectively abolishes the cyclic flow reduction in canine model of unstable angina with much less prolongation of bleeding time than platelet 2b3a receptors antagonist. Animal studies have also shown that Declotana[®] has a quite favorable safety profile compared with other platelet inhibitors. It is expected that Declotana[®] could have an important role in preventing thrombosis and plaque progression at sites of pathological endothelial injury, contributing to the treatment of unstable angina as well as to reduction of thrombosis in patients undergone PTCA and stenting. The Group has obtained patent in US and additional patent applications are underway.

About Lee's

Lee's Pharmaceutical Holdings Limited, a specialty biopharmaceutical company operating in China for over 14 years, was successfully listed on the Growth Enterprise Market (GEM) of the Stock Exchange of Hong Kong Limited in 2002. It is a fully integrated biopharmaceutical company with a solid infrastructure in both drug and clinical development. In addition, it carries out regulatory matters as well as manufacturing, sales and marketing activities throughout China. Lee's currently markets six products in China, and focuses its development efforts on various clinical areas, including

cardiovascular and infectious diseases, dermatology, oncology, gynecology and others with more than 15 products currently at different development stages. This is the result of both internal R&D activities as well as from their recent acquisition of licensing and distribution rights from various US, Japan and European partners.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com